Raymond James & Associates’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-27,800
| Closed | -$93K | – | 3829 |
|
|
2019
Q4 | $93K | Sell |
27,800
-300
| -1% | -$954 | ﹤0.01% | 3484 |
|
|
2019
Q3 | $85K | Buy |
28,100
+100
| +0.4% | +$281 | ﹤0.01% | 3404 |
|
|
2019
Q2 | $67K | Hold |
28,000
| – | – | ﹤0.01% | 3471 |
|
|
2019
Q1 | $105K | Buy |
28,000
+100
| +0.4% | +$375 | ﹤0.01% | 3381 |
|
|
2018
Q4 | $100K | Sell |
27,900
-9,600
| -26% | -$41.7K | ﹤0.01% | 3303 |
|
|
2018
Q3 | $215K | Sell |
37,500
-4,300
| -10% | -$24.6K | ﹤0.01% | 3257 |
|
|
2018
Q2 | $209K | Buy |
41,800
+3,300
| +9% | +$17K | ﹤0.01% | 3239 |
|
|
2018
Q1 | $198K | Hold |
38,500
| – | – | ﹤0.01% | 3140 |
|
|
2017
Q4 | $231K | Sell |
38,500
-4,000
| -9% | -$24.1K | ﹤0.01% | 2978 |
|
|
2017
Q3 | $236K | Hold |
42,500
| – | – | ﹤0.01% | 2943 |
|
|
2017
Q2 | $197K | Buy |
42,500
+500
| +1% | +$2.23K | ﹤0.01% | 2993 |
|
|
2017
Q1 | $208K | Buy |
42,000
+1,000
| +2% | +$9.62K | ﹤0.01% | 2913 |
|
|
2016
Q4 | $455K | Sell |
41,000
-4,200
| -9% | -$39.5K | ﹤0.01% | 2394 |
|
|
2016
Q3 | $419K | Buy |
+45,200
| New | +$378K | ﹤0.01% | 2395 |
|
Raymond James & Associates's FOMX Position: Q1 2020 in Review
Raymond James & Associates sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 27,800 shares — an estimated $93K sold.
Raymond James & Associates first reported a position in FOMX in Q3 2016 and held it in 14 quarters. The position peaked at $455K in Q4 2016. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- Raymond James & Associates reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- Raymond James & Associates sold 27,800 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $93K.
- Raymond James & Associates first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2016 and held it in 14 quarters.
- Raymond James & Associates's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $455K in Q4 2016.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.